Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1978 1
1980 1
1982 4
1983 1
1984 2
1985 4
1986 5
1987 4
1988 8
1989 2
1990 6
1991 8
1992 10
1993 3
1994 7
1995 6
1996 8
1997 6
1998 7
1999 3
2000 4
2001 2
2002 7
2003 6
2004 5
2005 7
2006 7
2007 10
2008 20
2009 13
2010 19
2011 16
2012 19
2013 26
2014 29
2015 29
2016 38
2017 41
2018 40
2019 57
2020 46
2021 67
2022 62
2023 75
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

695 results

Results by year

Filters applied: . Clear all
Page 1
Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy.
Wang H, Liu B, Wei J. Wang H, et al. Cancer Lett. 2021 Oct 1;517:96-104. doi: 10.1016/j.canlet.2021.06.008. Epub 2021 Jun 12. Cancer Lett. 2021. PMID: 34129878 Review.
Accumulating evidence has shown that alterations of B2M gene and B2M proteins contribute to poor reaction to cancer immunotherapies by dampening antigen presentation. Here, we discuss the basic biological functions of B2M, its distribution in a spectru …
Accumulating evidence has shown that alterations of B2M gene and B2M proteins contribute to poor reaction to cancer imm …
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL. Barkal AA, et al. Nature. 2019 Aug;572(7769):392-396. doi: 10.1038/s41586-019-1456-0. Epub 2019 Jul 31. Nature. 2019. PMID: 31367043 Free PMC article.
Here we show that CD24 can be the dominant innate immune checkpoint in ovarian cancer and breast cancer, and is a promising target for cancer immunotherapy. ...These data reveal CD24 as a highly expressed, anti-phagocytic signal in several cancers and …
Here we show that CD24 can be the dominant innate immune checkpoint in ovarian cancer and breast cancer, and is a promising ta …
Whole blood ACTB, B2M and GAPDH expression reflects activity of inflammatory bowel disease, advancement of colorectal cancer, and correlates with circulating inflammatory and angiogenic factors: Relevance for real-time quantitative PCR.
Bednarz-Misa I, Neubauer K, Zacharska E, Kapturkiewicz B, Krzystek-Korpacka M. Bednarz-Misa I, et al. Adv Clin Exp Med. 2020 May;29(5):547-556. doi: 10.17219/acem/118845. Adv Clin Exp Med. 2020. PMID: 32424999 Free article.
BACKGROUND: The effect of bowel inflammation and cancer on the expression of the most prevalent internal controls: ACTB, GAPDH and B2M in whole blood is unknown, although at least GAPDH occurred to be tightly regulated and suspected of supporting cancer growt …
BACKGROUND: The effect of bowel inflammation and cancer on the expression of the most prevalent internal controls: ACTB, GAPDH and …
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects.
Wu X, Li T, Jiang R, Yang X, Guo H, Yang R. Wu X, et al. Mol Cancer. 2023 Dec 2;22(1):194. doi: 10.1186/s12943-023-01899-4. Mol Cancer. 2023. PMID: 38041084 Free PMC article. Review.
The molecules of Major histocompatibility class I (MHC-I) load peptides and present them on the cell surface, which provided the immune system with the signal to detect and eliminate the infected or cancerous cells. In the context of cancer, owing to the crucial imm …
The molecules of Major histocompatibility class I (MHC-I) load peptides and present them on the cell surface, which provided the immune syst …
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. Zaretsky JM, et al. N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13. N Engl J Med. 2016. PMID: 27433843 Free PMC article.
A truncating mutation in the gene encoding the antigen-presenting protein beta-2-microglobulin (B2M) was identified in a third patient. JAK1 and JAK2 truncating mutations resulted in a lack of response to interferon gamma, including insensitivity to its antiproliferative e …
A truncating mutation in the gene encoding the antigen-presenting protein beta-2-microglobulin (B2M) was identified in a third patien …
gammadelta T cells are effectors of immunotherapy in cancers with HLA class I defects.
de Vries NL, van de Haar J, Veninga V, Chalabi M, Ijsselsteijn ME, van der Ploeg M, van den Bulk J, Ruano D, van den Berg JG, Haanen JB, Zeverijn LJ, Geurts BS, de Wit GF, Battaglia TW, Gelderblom H, Verheul HMW, Schumacher TN, Wessels LFA, Koning F, de Miranda NFCC, Voest EE. de Vries NL, et al. Nature. 2023 Jan;613(7945):743-750. doi: 10.1038/s41586-022-05593-1. Epub 2023 Jan 11. Nature. 2023. PMID: 36631610 Free PMC article.
We next identified a strong association between B2M inactivation and increased infiltration by gammadelta T cells in MMR-d cancers. ...By comparing paired tumour samples from patients with MMR-d colon cancer that were obtained before and after dual PD-1 and C …
We next identified a strong association between B2M inactivation and increased infiltration by gammadelta T cells in MMR-d cancers …
β2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages.
Li D, Zhang Q, Li L, Chen K, Yang J, Dixit D, Gimple RC, Ci S, Lu C, Hu L, Gao J, Shan D, Li Y, Zhang J, Shi Z, Gu D, Yuan W, Wu Q, Yang K, Zhao L, Qiu Z, Lv D, Gao W, Yang H, Lin F, Wang Q, Man J, Li C, Tao W, Agnihotri S, Qian X, Shi Y, You Y, Zhang N, Rich JN, Wang X. Li D, et al. Cancer Res. 2022 Sep 16;82(18):3321-3334. doi: 10.1158/0008-5472.CAN-22-0507. Cancer Res. 2022. PMID: 35841593
Inhibition of B2M attenuated GSC survival, self-renewal, and tumor growth. B2M-induced TGFbeta1 secretion activated paracrine SMAD and PI3K/AKT signaling in TAMs and promoted an M2-like macrophage phenotype. These findings reveal tumor-promoting functions of B2M …
Inhibition of B2M attenuated GSC survival, self-renewal, and tumor growth. B2M-induced TGFbeta1 secretion activated paracrine …
Antitumor Immune Responses in B2M-Deficient Cancers.
Torrejon DY, Galvez M, Abril-Rodriguez G, Campbell KM, Medina E, Vega-Crespo A, Kalbasi A, Comin-Anduix B, Ribas A. Torrejon DY, et al. Cancer Immunol Res. 2023 Dec 1;11(12):1642-1655. doi: 10.1158/2326-6066.CIR-23-0139. Cancer Immunol Res. 2023. PMID: 37801341 Free PMC article.
beta2-microglobulin (B2M) is a critical component of the MHC class I molecule and is required to present tumor antigens to T cells. ...The more aggressive B16 without B2M expression only partially responded to the IL2 agonist, and this was dependent on NK cells. ...
beta2-microglobulin (B2M) is a critical component of the MHC class I molecule and is required to present tumor antigens to T cells. . …
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Gettinger S, et al. Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12. Cancer Discov. 2017. PMID: 29025772 Free PMC article.
Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to I …
Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. CRISPR-mediated knockout of B2m …
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.
Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Parry EM, et al. Nat Med. 2023 Jan;29(1):158-169. doi: 10.1038/s41591-022-02113-6. Epub 2023 Jan 9. Nat Med. 2023. PMID: 36624313 Free PMC article.
We discovered RS-specific somatic driver mutations (including IRF2BP2, SRSF1, B2M, DNMT3A and CCND3), recurrent copy-number alterations beyond del(9p21)(CDKN2A/B), whole-genome duplication and chromothripsis, which were confirmed in 45 independent RS cases and in an extern …
We discovered RS-specific somatic driver mutations (including IRF2BP2, SRSF1, B2M, DNMT3A and CCND3), recurrent copy-number alteratio …
695 results